Abstract
Drug target identification is one of the most important aspects of pre-clinical development yet it is

23
also among the most complex, labor-intensive, and costly. This represents a major issue, as lack 
85
(favoring instead, the discovery of genes of the same class as the known drug-targets), the small 86 number of drugs used in the study (<500), or lack of experimental target validation [19] [20] [21] . To 87 overcome these limitations, we introduce BANDIT, a novel drug-target prediction platform.
88
BANDIT achieves unprecedented target-identification accuracy, without any reliance on gene-89 based similarities (making it broadly applicable to newly discovered compounds), uncovers novel 90 targets for the treatment of cancer, and can be used to quickly pinpoint potential therapeutics with 91 novel mechanisms of action to accelerate drug development.
93
A novel combinatorial Big-Data Approach leads to a large increase in predictive power
95
In the age of "Big Data" there has been an explosion of techniques that permit genomic, chemical,
96
clinical, and pharmacological measurements to characterize a small molecule's mechanism.
97
Many such measurements are either already published or are reasonably straightforward to 98 perform. We hypothesized that integrating the multiple, independent pieces of evidence provided 
108
For each data type we calculate a similarity score for all drug pairs with known targets. Since 109 each dataset uses a distinct reporting metric, the similarity calculation was specific to the data 110 type being considered ( Figure S1 ; Methods). Previous approaches have argued that high 111 similarity in one feature indicates high similarity in others, implying that only one or two data types
112
are sufficient for target prediction since others can be inferred 28 . However, using our vastly 113 expanded dataset, we found little overall correlation across different similarity scores ( Figure 1A; 114 Figure S2 ). These results suggest that each data type is measuring a distinct aspect of a 115 molecule's activity and that individual features for a given drug cannot be extrapolated based on 116 other data types. This shortcoming further supported our hypothesis that a novel approach that
117
integrates independent data types could significantly improve target prediction accuracy.
119
We next separated drug pairs into those that shared at least one known target (>34,000 pairs)
120
and pairs with no known shared targets (>1,250,000 pairs). We applied a Kolmogorov-Smirnov 121 test to each similarity score and used the associated D statistic to calculate the degree a given 122 data type could separate out drug pairs that shared targets ( Figure 1B) . We found that all
123
features were able to significantly separate the two classes (P < 2e-16), and structural similarity 124 was found to be the most discriminative among all features evaluated (D Structure = 0.39).
125
Additionally, we discovered that similarity across an unbiased set of bioassays and the relatively 
129
information not only identifies the strengths of each data type, but will also allow researchers to
130
efficiently prioritize experiments when faced with limited resources.
132
For every drug pair, BANDIT converts each individual similarity score into a distinct likelihood 133 ratio. These individual likelihood ratios are then combined within a Naïve Bayes framework to 134 obtain a total likelihood ratio (TLR) that is proportional to the odds of two drugs sharing a target
135
given all available evidence ( Figure 1C ; Methods). We calculated TLRs for all possible drug 136 pairs with known targets and the output was evaluated using 5-fold cross validation. We observed
137
an Area Under the Receiver Operating Curve (AUROC) of 0.89 -higher than any competing 138 approach 13,28 -demonstrating that BANDIT's integrative approach can accurately identify drugs 139 that share targets. We recomputed the AUROC while varying the number of included data types
140
and observed an overall increase in predictive power as we added new data types (Figure 2A ).
141
Furthermore we observed a steady increase in predictive power regardless of the addition order.
142
This result verified the power of BANDIT's "Big Data" approach and demonstrated how separate 143 information sources can be combined to yield predictions more powerful than those obtained from Figure S6 ). This result supports 163 using BANDIT to guide experimental screens while minimizing operational costs.
165
Moving forward from shared-target predictions, we examined whether for a given drug BANDIT
166
could be used to predict a specific binding target from our database of over 1,600 
173
-measured by whether BANDIT correctly identified a known drug target -steadily increased
174
( Figure 2D ). The accuracy level eventually reached ~90%, demonstrating that BANDIT could be 175 used to accurately identify specific targets for a diverse set of small molecules.
177
We 
217
From our list of top anti-microtubule drug predictions we obtained a set of 24 compounds with
218
varying structures for experimental testing (Methods , Table S1 ). We chose the human breast 
226
To more accurately quantify the extent of drug-target engagement, we employed a second 227 biochemical assay quantifying the effect that each small molecule exerted on the equilibrium 228 between microtubule polymers and soluble tubulin, following 6 hours of treatment ( Figure S14 ).
229
Our results confirmed and corroborated the microscopy results, further revealing that while 
233
Taken together, these experiments confirmed the predicted targets and mechanism of action for 234 the majority of the newly identified microtubule inhibitors. While further testing will be needed 235 before these small molecules can be used clinically, these results do demonstrate BANDIT's 236 target prediction accuracy and how it can be used on compound libraries to identify small 237 molecules acting with a specific mode of action on specific targets, for further investigation.
239
To inform future clinical development for these newly identified microtubule inhibitors, we next 
256
-fold more resistant to Eribulin than the parental cells and exhibited cross-resistance to all
257
classes of clinically used microtubule-depolymerizing drugs (Table S2) . To test whether the drug- 
270
Compound No 15, which was the most active of the 4 compounds, was tested using cytotoxicity 271 assays and was found to almost completely reverse drug-resistance from 7050-fold observed
272
with Eribulin down to 4-fold (Table S2) 
304
To test these predicted targets we performed in vitro profiling of GPCR activity using a 305 hetereologous reporter assay for arrestin recruitment, which is a hallmark of GPCR activation 51 .
306
Our results indicated that ONC201 selectively antagonized the D2-like (DRD2/3/4L), but not D1- 
309
antagonized both short and long isoforms of DRD2 and DRD3, with weaker potency for DRD4.
310
Further characterization of ONC201-mediated antagonism of arrestin recruitment to DRD2L was 311 assessed by a Gaddam/Schild EC50 shift analysis, which determined a dissociation constant of 
321
its biological activity ( Figure S17F ). In summary, these studies establish that ONC201 selectively
322
antagonizes the D2-like subfamily of dopamine receptors, which is an "unconventional" target for
323
oncology drugs and further demonstrate BANDIT's ability to act as a tool to advance drug 324 development.
326
This unexpected discovery on the DRD2L being a direct-binding target for ONC201, has also led 
333
BANDIT can determine drug mechanisms and can help understand the drug "universe"
335
Following validation that BANDIT could accurately determine the specific targets for small 336 molecules, we then examined how it could also be used to understand the target binding 
346
mechanism identification: first using BANDIT to predict targets for an orphan small molecule,
347
followed by clustering with other drugs known to act on the same target to discern MoA.
349
We next used BANDIT to get an overview of how different classes of drugs, spanning the entire 
445
Calculating similarity scores: 
461
Calculating correlations between similarity types:
463
For each pair of similarity scores we separated out drug pairs where both similarity types were 464 measured and plotted the different similarity scores against one another (Figure 1a , Figure S2 ).
465
We computed the Pearson correlation coefficient (PCC) and the coefficient of determination (R 2 )
466
between each pair of similarity scores. Across all pairs, we observed a low correlation - 
471
Calculating the Total Likelihood Ratio:
473
For each data type BANDIT calculates a "likelihood ratio" L(s n ) is defined as the fraction of drug 474 pairs with a shared target (ST pairs) having a given similarity score s n, divided by the fraction of 475 the non-ST pairs with the same similarity score:
Eq. 1:
480
Our previous analysis highlighted the minimal correlation between the similarity types and how 481 data types could be modeled independently under a Naïve Bayes framework. This assumption of 482 independence implies that the joint probability of two drugs sharing a target given a set of 483 similarity scores can be modeled as the product involving individual similarity scores. Therefore 484 the total likelihood ratio L(s) can be expressed as the product of the individual likelihood ratios:
486
Eq. 2:
487 488
490
The total likelihood ratio (TLR) is then proportional to the odds of two drugs sharing a given target 491 n given sources of information
493
Overall we decided to use this Bayesian framework for multiple reasons, such as the readily 494 interpretable nature of a likelihood ratio compared to other more complicated machine learning 495 scores and the ability to easily add in new data types as they become available.
497
Testing Against Drugs with Known Targets:
499
Drug targets were extracted from DrugBank and drug pairs were classified as a "shared-target" 500 pair if they had at least 1 target in common. We used 5-fold cross validation to split our set of drug
501
pairs into a test and training set containing 20% and 80% of the drug pairs respectively. We sub- 
509
We performed this analysis with the TLR output while varying the number of data types being 510 considered and found a significant increase in the predictive power, measured by the AUROC, as
511
we increased the number of included datasets (Figure 2A ). We computed two sets of ROC curves
512
-one where we required drugs have available data in each included data type (our preferred 513 method) and another where we imputed the data type median for each missing data type. We 514 varied the order in which datasets were added and observed a positive relationship between
515
AUROC value and the number of included data types regardless of the addition order.
516
Furthermore we used a KS test to measure how our TLR value could separate out ST and non-
517
ST pairs and saw that in each case our TLR value outperformed any individual variable ( Figure   518 S4). We repeated this analysis increasing the minimum number of data types we required a pair 519 of compounds to have and saw the separation steadily improve (D = .44 to .69).
521
Replicating Kinase Experimental Screen
523
We first separated out the kinases in the Peterson et al. database that were classified as BANDIT orphan small molecules -molecules that were in at least two of the considered BANDIT 525 databases and had no known targets. For each orphan kinase inhibitor we used BANDIT to 526 predict shared target drugs. Each known kinase target of the shared target drugs was classified 527 as a potential kinase target of the orphan inhibitor. We then observed that the "percent remaining 528 kinase activity" was significantly lower between the orphan kinase inhibitors and the BANDIT 529 predicted kinases than between the orphan inhibitors and any non-predicted kinases (Wilcoxon
530
Rank Sum Test P = 3.62e−06) ( Figure S6 ).
531
Specific Target Voting
533
For each orphan small molecule we identified all shared target drug predictions, or any drugs with 534 known targets that exceeded a given BANDIT likelihood ratio. For each shared target drug 535 prediction, we compiled all known targets of that given drug and ranked specific protein targets 536 based on how often it appeared as known target in shared drug target predictions. "Votes" for 537 particular protein targets were weighted based on the likelihood ratio of the shared target 538 prediction they originated from. The top voted target for each orphan small molecule that we 539 tested was then predicted to be a novel specific target (Figure 2e ).
541
To test the accuracy, we used leave-one-out cross validation on our test set of drugs with known 542 targets. For each drug we used BANDIT to compare it to all other drugs with known targets and 543 identify the top ranked target for the tested drug. This was repeated for every drug in our test set
544
and we calculated how often the top ranked target was a known target of the drug being tested.
545
We recomputed these accuracies while varying the likelihood ratio cutoff for a drug pair to be 546 considered a shared-target prediction. As expected we observed a steady rise in accuracy as we 
551
Identification of Novel Anti-Microtubule Small Molecules
553
For each orphan small molecule in BANDIT (defined as a molecule tested in any of the individual 554 databases but without any known targets in DrugBank) we used the BANDIT voting protocol to 555 predict specific protein targets. We required that each orphan small molecule be in at least 3 of
556
BANDIT's databases, leaving us with a set of ~15,000 small molecules. To refine our initial list of 557 predictions into a high confidence set, we required a TLR cutoff of 500, that each predicted target 558 appear in the majority of shared target predictions, and that the highest ranked target appear in 559 the top shared target prediction for each orphan molecule. From this list of high confidence 560 predictions we identified a set of small molecules predicted to bind to microtubules.
562
For each predicted microtubule inhibitor (MTI) we examined how it related to known MTIs using a 563 network approach ( Figure S7 ). We required that each predicted MTI have a TLR greater than 500
564
with at least two known MTIs. Each edge in our network represents a predicted shared target 565 interaction with the length and width of each corresponding to the strength of the prediction
566
(measured by the TLR value). We used the Fruchterman Reingold projection within the R igraph 567 package. We observed a distinct clustering of known MTIs based on their mechanism of action.
569
Most of the novel MTIs we predicted were not easily obtained, thus we specifically focused on the 570 subset that we could obtain from the National Cancer Institutes Developmental Therapeutics
571
Program (Table S1 ).
573
Microtubule Imaging/Testing 574 575 
593
A Fisher's exact test was used to determine whether the number of observed successes -
594
defined as a predicted microtubule inhibitor showing an effect against microtubules in imaging -
595
was greater than what would be expected by random chance. To determine the background 596 probability we used the number of drugs with known targets in our database that were known to 597 target microtubules (~ 1%).
599
Microtubule Effect Quantification 600 601 
614
Three biological repeats were performed ( Figure S14 ).
616
Imaging of Treatment Against Resistant Cell Lines
618
1A9-ERB is a clone of the 1A9 human ovarian carcinoma cell line resistant to the effects of 
645
Bottom)/(1+10^((LogEC50-X)*HillSlope)), where X is the log concentration of compound.
647
For Schild analysis, data was normalized for percent efficacy using the appropriate controls and 648 fitted to a Gaddum/Schild EC50 shift using global fitting, where Y=Bottom + (Top-
649
Bottom)/(1+10^((LogEC-X)*HillSlope)), Antag=1+(B/(10^(-1*pA2)))^SchildSlope and
650
LogEC=Log(EC50*Antag). EC50 / IC50 analysis was performed in CBIS data analysis suite
651
(Cheminnovation) and Schild analysis performed in GraphPad Prism 6.0.5 ( Figure 5 , Figure S17 ).
653
The kinase assay and nuclear hormone receptor profiling (S16) were performed as previously 654 described by Reaction Biology Corp and DiscoverX respectively 61-63 .
656
Drug Mechanism Clustering
658
For each drug pair we converted the TLR between them into a distance metric used to estimate
659
"closeness" between any two drugs:
661
Eq. 3:
663
We next separated all drugs know to target microtubules that were in at least 3 of BANDIT's 664 dataset. With the BANDIT distance metric as an input we created a hierarchical cluster of all 665 known MTIs using the hclust R method with an "average" based clustering method. Known MTIs
666
were labeled based on whether they were known to polymerize or depolymerize microtubules,
667
and we observed a distinct separation based on the mechanism of action (MoA). We repeated 668 this clustering while removing drug structures from our likelihood calculations and continued to 669 see a MoA-based separation ( Figure S18 ). This revealed that BANDIT's clustering approach is 670 not dependent on any single data type, and that observed results are due to BANDIT's integrative 671 approach. This analysis was then repeated using similar conditions for known protein kinases.
673
Drug "Universe" Clustering
675
Using the same protocol as was used to create the MTI network, we created a network of all 
683
To get a better understanding of how orphan small molecules fit into this drug "universe" we 684 computed the distance between every pair of small molecules and used multi-dimensional scaling 685 to visualize the overall structure ( Figure S19 ). We used the same distance metric as described in 686 the mechanism of action clustering section to create a distance matrix between all small 687 molecules (known drugs and orphan) and used the R cmdscale package for the multi-dimensional 688 scaling. We noticed a definite structure with known drugs tightly clustering around each other,
689
while orphan molecules had a more diffuse organization. One explanation for this structure is that 690 drugs with known targets are more likely to be used to treat patients and thus may have similar 691 effects due to safety precautions, whereas orphan molecules which have not gone through 
